Seeking Alpha

A SMARTER GREEK

A SMARTER GREEK
Send Message
View as an RSS Feed
View A SMARTER GREEK's Comments BY TICKER:
Latest  |  Highest rated
  • After Hours Gainers / Losers [View news story]
    Any good data / prediction on DXCM earnings and or WWAV. /? Make my life easier I hope!
    Aug 5, 2015. 08:15 AM | Likes Like |Link to Comment
  • AbbVie: Is There Enough Time To Promote New Drugs Before Humira Patent Expired? [View article]
    Good morning! Has anyone looked at the potential and the current state of PCYC's R/A innovation? If you do it just might prove very exciting with a huge potential.
    I'm waiting for the Amreican National Oncology Conference later this month in Philly, where hopefully there will be more updates on PCYC partnerships re: Solid tumors. Plus their quareterly report usually by 2nd week of May. Financials and more updates.
    Apr 7, 2015. 08:07 AM | 2 Likes Like |Link to Comment
  • AbbVie: Is There Enough Time To Promote New Drugs Before Humira Patent Expired? [View article]
    $Aabv& $PCYC 2 weeks ago FDA gave go ahead to Phase2 for PCYC new R/A drug based on preliminary results. Hey maybe they have another blockbuster and J & J does not have a piece of this baby! Might this be another reason ABBV was highest bidder?
    Smarter Greek
    Check it out, most analyst have missed this. Also hopefully by 4th quarter PCYC might be getting 1st Line use approval from FDA for Imbruvica applied for past May! That should rocket sales even further! Well done ABBV and PCYC!
    Apr 3, 2015. 10:38 AM | Likes Like |Link to Comment
  • Pharmacyclics: Is A $19 Billion Valuation Reasonable? [View article]
    Check out the late friday press releases. Re; Colon and Tumor preliminary results with their partners! Un believable. results! PCYC will become a main add on and block buster also used with other products. ( very smart!) Also FDA gave go ahead with further Phase testing on their new R/A product based on preliminary testing......All that can add huge and further potential.
    Feb 28, 2015. 04:04 PM | 1 Like Like |Link to Comment
  • Pharmacyclics Announces Presentation of Phase III and Long Term Follow Up Data on IMBRUVICA™ in Chronic Lymphocytic Leukemia (CLL) at ASCO [View article]
    Once this makes it through, this is the Holy Grail for a new fast/safe. and effective handling of blood cancers! Just the beginning!
    Apr 22, 2014. 07:10 AM | Likes Like |Link to Comment
  • "Not cheap" Pharmacyclics is headed higher on Ibrutinib potential: JPMorgan [View news story]
    tremendous move! Great product saving and prolonging life, with much less if any bad side effects!
    Bob Duggan the CEO/Chrmn has done this before. ISRG at 12 up to
    500+ now at 350.
    Same guy, great visionary that gets things done! Always first with new technology that works and changes the field.
    Sep 26, 2013. 12:24 PM | 2 Likes Like |Link to Comment
  • Pharmacyclics (PCYC) submits an NDA for ibrutinib (developed with JNJ's Janssen) for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. The drug has Breakthrough Therapy designation for both indications and is a major catalyst for the shares. This is one to watch closely given the takeout chatter around ONXX. In other company news, Jesse McGreivy is promoted to Chief Medical Officer. [View news story]

    Great news ahead of schedule! Remember CEO/Chrm of this baby was also very insturmental with launching ISRG and got involved at $12.00! now over $450 and billions in sales.

    He is smart and cares a lot about helping others!
    Jul 10, 2013. 08:09 AM | Likes Like |Link to Comment
  • Pharmacyclics (PCYC) submits an NDA for ibrutinib (developed with JNJ's Janssen) for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. The drug has Breakthrough Therapy designation for both indications and is a major catalyst for the shares. This is one to watch closely given the takeout chatter around ONXX. In other company news, Jesse McGreivy is promoted to Chief Medical Officer. [View news story]
    Ahead of schedule! Nice....remember CEO/Chrmn of this company is same person that launched the technology responsible for and thus ISRG for 12 to 450+. His involvement was at $12.00
    He is a smart dude and good guy who cares a lot for others!
    Jul 10, 2013. 08:07 AM | Likes Like |Link to Comment
  • Pharmacyclics (PCYC +9.5%) trades higher today after RBC Capital ups the shares to Outperform and raises its price target to $100 from $70. The firm cites optimism over a number of upcoming catalysts for its leukemia drug Ibrutnib, which is being jointly developed by PCYC and JNJ's Janssen Pharmaceuticals. [View news story]
    Mr. Duggan the CEO and Chairman..is repeating again with a phenominlal product(s), and successfull company in PCYC as he did
    with ISRG..from 12 to 500!
    Real company, great products, good management..de ja vu!
    May 13, 2013. 01:17 PM | 1 Like Like |Link to Comment
  • Pharmacyclics (PCYC +1.7%) gets a bump higher this morning after announcing its Phase III clinical trial using Ibrutinib versus Chlorambucil to treat chronic lymphocytic leukemia and small lymphocyctic lymphoma has enrolled its fifth patient. The enrollment subsequently triggers a fourth $50M milestone payment obligation from JNJ's Janssen Biotech, who is collaborating with PCYC on Ibrutinib in oncology. On Monday, the drug was granted a 3rd "Breakthrough Therapy Designation" by the FDA. [View news story]
    Mr. Duggan the COB and CEO is doing it again witth PCYC! He did it with ISRG from 12 to over $500.00 and changed the robotic surgery industry and he is doing it again in the Oncology industry. We need more guys like him.
    Apr 11, 2013. 10:38 AM | Likes Like |Link to Comment
  • After The Bloodbath, Where Does Pharmacyclics Go From Here? [View article]
    You have a very determined and focused COB/CEO with PCYC. His goal is to bring to market a product(s) that really make a difference and help mankind.
    As he did with ISRG. when he became a part of it basically very little sales, now billions in sales, $10-$12.00, cklosed today at $524.

    I like to bet on a winner.
    Nov 15, 2012. 04:28 PM | Likes Like |Link to Comment
  • After The Bloodbath, Where Does Pharmacyclics Go From Here? [View article]
    to Mr. Li and others ( I alreadys sent this but didn't print?)
    Thanks for clarification. The insiders emplowees/directors etc own over 20 % correct but Mr. Duggan the COB owns about 80-90% of that. He shas stated he is not selling. ( By the way he is the same person that gace birth and is still on the Board of the Da Vinci robotics machine..ISRG!) If you examine the stock options the have an average vested perios of 3-5 years. So if they do need to sell because of the change in the tax laws comint, maybe 100,00+ shares if tha, nothing! Also the Leukimia Phas 2 and 3 testinghas been ophenominal and I wouldn't be surprised if another payment shortl! As fot eh MM tsing it was very preliminary and only with 14 out of 420 patients! They has some good resuklts anyway so they are just increases the dosage. Not threat to J & J continued investment at all anothe 725 mil to go!!!
    A
    Nov 15, 2012. 11:06 AM | Likes Like |Link to Comment
  • Why Immunogen Is Undervalued [View article]
    RE: PCYC also to Mr. Li,
    Thanks for some clarification on the 19% drop in PCYC. What should be known and further clarified is that the employees/officers etc stock which is held, nearly 80-90% of that is owned by the COB Mr. Bob Duggan and he is Not selling per his statementt. Also if you go back and research most stock options they are all vested options take average 3-5 years+ to vest. So I figure max if some need to sell before year end because this tax laws changing is maybe 100,000 shares+ if that!..nothing! Also about the MM testing only 14 people were tested and there were some good results anyway,, however not up to their standards, but still had good effects, so they are simply increasing the dosage and with a much bigger group 400+ testing. The leukemia testing in phase 2 and 3 has been phenomenal! Hope this helps clear it all up further.
    Andy Golden Greek
    Nov 15, 2012. 10:50 AM | Likes Like |Link to Comment
  • Pharmacyclics' (PCYC) Phase II trial of its ibrutinib drug in patients with mantle cell lymphoma, a rare type of non-Hodgkin's lymphoma, enrolls its 5th patient, thereby triggering a second milestone payment of $50M from J&J (JNJ) unit Janssen Biotech. Additional $50M payments could be triggered up to a total of $250M. (First payment[View news story]
    Been waiting for PCYC to sell of a little to get a little more. That hasn't worked! The train gas left the station!
    Guess options best way!
    Aug 20, 2012. 09:02 AM | Likes Like |Link to Comment
  • Pharmacyclics' (PCYC) Phase II trial of its ibrutinib drug in patients with mantle cell lymphoma, a rare type of non-Hodgkin's lymphoma, enrolls its 5th patient, thereby triggering a second milestone payment of $50M from J&J (JNJ) unit Janssen Biotech. Additional $50M payments could be triggered up to a total of $250M. (First payment[View news story]
    Been waiting for it to sell off at least a little, so I can get a little more! Still waiting!

    I guess options the brstw ay right now.

    The Greek
    Aug 20, 2012. 09:01 AM | Likes Like |Link to Comment
COMMENTS STATS
20 Comments
6 Likes